Pradhan et al. have demonstrated that GLP-1 receptor agonists and SGLT-2 inhibitors were capable of reducing severe exacerbations compared to sulfonylureas in patients diagnosed with COPD. Here, GLP1R is linked to chronic obstructive pulmonary disease.